Arvelle Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 60

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $960M

  • Investors
  • 1

Arvelle Therapeutics General Information

Description

Operator of a biopharmaceutical company intended to deliver innovative treatments to patients suffering from CNS disorders. The company's therapies serve patients suffering from central nervous system disorders for debilitating neurological and neuromuscular diseases and are responsible for the development and commercialization of Cenobamate, enabling clinicians to provide proper medical care for focal seizures of patients.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Acquirer
Angelini Pharma
Corporate Office
  • Zählerweg 6
  • 6301 Zug
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arvelle Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 02-Feb-2021 $960M 00000 00000 Completed Generating Revenue
2. Early Stage VC (Series A) 26-May-2020 00000 00000 Completed Generating Revenue
1. Corporate 01-Feb-2019 Completed Startup
To view Arvelle Therapeutics’s complete valuation and funding history, request access »

Arvelle Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to deliver innovative treatments to patients suffering from CNS disorde
Drug Discovery
Zug, Switzerland
60 As of 2021
00000
00000 0000-00-00
000000&0 00000

000000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000 000000000
Kalamazoo, MI
00 As of 0000
0000
000000 - 000 0000

000000

im veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commo
0000000000000
Julich, Germany
00 As of 0000
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arvelle Therapeutics Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Metabolic Solutions Development Venture Capital-Backed Kalamazoo, MI 00 0000 000000 - 000 0000
Priavoid Accelerator/Incubator Backed Julich, Germany 00 000000000000
SAGE Therapeutics Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
Minerva Neurosciences Formerly VC-backed Burlington, MA 0 00000 000000000 00000
Vertex Pharmaceuticals Formerly VC-backed Boston, MA 0000 00.000 000000&0
You’re viewing 5 of 36 competitors. Get the full list »

Arvelle Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arvelle Therapeutics Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Andera Partners PE/Buyout Minority 000 0000 000000 0
BRV Capital Management Growth/Expansion Minority 000 0000 000000 0
EQT Life Sciences Venture Capital Minority 000 0000 000000 0
Eight Roads Corporate Venture Capital Minority 000 0000 000000 0
F-Prime Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Arvelle Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cenobamate Drug Development and Commercial rights for Europe 20-Feb-2019 000000000 00000 Buildings and Property
To view Arvelle Therapeutics’s complete investments history, request access »

Arvelle Therapeutics FAQs

  • When was Arvelle Therapeutics founded?

    Arvelle Therapeutics was founded in 2019.

  • Who is the founder of Arvelle Therapeutics?

    Mark Altmeyer, Gregory Weinhoff MD, and Ilise Lombardo MD are the founders of Arvelle Therapeutics.

  • Where is Arvelle Therapeutics headquartered?

    Arvelle Therapeutics is headquartered in Zug, Switzerland.

  • What is the size of Arvelle Therapeutics?

    Arvelle Therapeutics has 60 total employees.

  • What industry is Arvelle Therapeutics in?

    Arvelle Therapeutics’s primary industry is Drug Discovery.

  • Is Arvelle Therapeutics a private or public company?

    Arvelle Therapeutics is a Private company.

  • What is the current valuation of Arvelle Therapeutics?

    The current valuation of Arvelle Therapeutics is 00000.

  • What is Arvelle Therapeutics’s current revenue?

    The current revenue for Arvelle Therapeutics is 000000.

  • How much funding has Arvelle Therapeutics raised over time?

    Arvelle Therapeutics has raised $223M.

  • Who are Arvelle Therapeutics’s investors?

    Andera Partners, BRV Capital Management, EQT Life Sciences, Eight Roads, and F-Prime Capital are 5 of 9 investors who have invested in Arvelle Therapeutics.

  • Who are Arvelle Therapeutics’s competitors?

    Metabolic Solutions Development, Priavoid, SAGE Therapeutics, Minerva Neurosciences, and Vertex Pharmaceuticals are some of the 36 competitors of Arvelle Therapeutics.

  • When was Arvelle Therapeutics acquired?

    Arvelle Therapeutics was acquired on 02-Feb-2021.

  • Who acquired Arvelle Therapeutics?

    Arvelle Therapeutics was acquired by Angelini Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »